Navigation Links
Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
Date:10/31/2011

responses to VGX-3100. Subjects will also be monitored for tolerability and safety. See the HPV-003 clinical trial protocol.

About Fierce VaccinesFierce Vaccines is a weekly update on the vaccine industry with a special focus on the innovations revolutionizing the development and production of vaccines. Fierce Vaccines reaches corporate executives and R&D leaders at vaccine developers and pharmaceuticals of all sizes. Editorial topics include vaccine R&D, sales and marketing, research breakthroughs, vaccine production, disruptive technologies, and next-generation vaccine therapeutics. Fierce Vaccines is one of the publications offered by Fierce Markets, whose newsletters deliver crucial industry news and insightful analysis to over a million industry leaders each day. http://www.fiercevaccines.com.

About VGX-3100Inovio's VGX-3100 is designed to raise immune responses against the E6 and E7 oncogenes common to HPV types 16 and 18, i.e. it targets four antigens. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The goal is to stimulate a T-cell immune response strong enough to cause the rejection of these infected or transformed cells from the body. The potential of such a therapeutic vaccine would be to treat precancerous dysplasias (CINs), cervical cancers, as well as other anogenital and head and neck cancers caused by these HPV types.

About Cervical Dysplasias/Cancers Human papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer. At any given time, approximately 10% of women worldwide are infected with HPV. While roughly 70% of HPV infections are cleared by the body on its own, persistent HPV can lead to dysplasia, or premalignant changes in cells, of the cervix. Resea
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services ... Asia Pacific Version" report to their offering. ... growing. Clinical laboratory testing is positioned to directly ... A range of dynamic trends are pushing market ...
(Date:5/5/2015)... 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... months ended March 31, 2015 and reaffirmed its revenue, ... 2015. First Quarter 2015 Highlights Include: ... of 72% as compared to $10.9 million for the ... non-GAAP EBITDA of $11.5 million, an increase of 170% as ...
(Date:5/5/2015)...   Cynosure, Inc. (Nasdaq: CYNO ), ... procedures and precision surgical applications worldwide, today reported financial ... First-Quarter Highlights: , North America product ... of $0.15 per share; GAAP earnings break-even , ... 2015 "Cynosure delivered 21 percent year-over-year top-line ...
Breaking Medicine Technology:Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 3ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 5ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 6ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 7ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 8ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... treat voiding dysfunctions, today reported financial results for the fourth ... Global sales grew 35% to $4.0 million in the ... million in the fourth fiscal quarter a year ago.  The ...
... 25, 2011 Just days after the one year ... sales representatives at Novartis Pharmaceuticals Corporation, the law firm ... identical class action on behalf of female sales representatives ... the amended complaint, there is an entirely new class ...
Cached Medicine Technology:Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 2Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 3Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 4Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 5Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 6Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 7Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 8Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 9Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 10Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011 11Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 2Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 3Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 4
(Date:5/5/2015)... Fayetville, AR (PRWEB) May 05, 2015 ... is collaborating with American Eagle Outfitters on ... that enhance natural beauty. , For the ... teaming with Aerie by American Eagle ; ... The brand's body-image campaign, called "Aerie REAL," uses ...
(Date:5/5/2015)... California (PRWEB) May 05, 2015 ... in San Francisco, leads an international initiative to examine ... to extend the human lifespan. Scientists at Igantia ... to women, from the initiation of her menstrual cycle ... possible mechanism for aging and, ultimately, extend the lifespan. ...
(Date:5/5/2015)... 05, 2015 Care Logistics ... called “Medicare Breakeven Challenges? A Model to ... ,     Formulas for two critical ... but should be ,     A model ... space” and ensures sustained efficient operations , ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Every year, news ... seasons. Turns out, the worst dry eye season is spring, ... spikes in most of the United States. The only season ... water advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ ... on her radio show of May 11, 2015. Kleyne is ...
(Date:5/5/2015)... Seattle, WA (PRWEB) May 05, 2015 Dealing ... be a strenuous and complicated task. Personal injury lawyers are ... lawyers are created equal. In their latest article , ... individuals should search for when choosing a personal injury lawyer ... a personal injury case is a waste of time if ...
Breaking Medicine News(10 mins):Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Care Logistics Publishes a New Hospital Guidebook for Achieving Medicare Breakeven 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3Health News:5 Top Qualifications for Personal Injury Lawyer Disclosed in Latest Article by The Jones Firm 2
... tobacco use in the Commonwealth's restaurants, taverns, and nightclubs, ... liquor-store sales as the House and Senate concluded the ... nearly midnight, lawmakers also approved a sales tax "holiday" ... up the state's flagging economy, and approved $102 million ...
... The House headed for a historic vote Friday night on ... marking the biggest expansion // of the politically popular entitlement ... moon and the stars have lined up in our favor," ... in the Capitol. "The time is upon us. It's now ...
... drug alternative to warfarin in reducing stroke among people with ... ximelagatran appears to be as effective as warfarin.// ,Warfarin ... of stroke because of its blood thinning capability. However, some ... bleeding and a possible interaction with food and other medications. ...
... a novel new drug is beneficial for patients with ... the first in a new class of drugs //to ... called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or CTLA4Ig. Preliminary research ... rheumatoid arthritis. Researchers from Belgium conducted a study to ...
... safe, and promising therapy option may be more effective in ... chronic skin disease that causes persistent redness on the nose ... acid gel to the faces of rosacea sufferers. //The new ... for rosacea. Typically it has a different formula and is ...
... psoriasis are at an increased risk for cancer, according ... psoriasis had a nearly three-fold increased rate of lymphoma.//,Psoriasis ... percent to 2 percent of the population. Patients with ... usually on the torso or arms that can be ...
Cached Medicine News:Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4Health News:House heads for Medicare drug vote, 2Health News:House heads for Medicare drug vote, 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: